Wells Fargo & Company MN Has $7.76 Million Holdings in Chemours Company (The) (NYSE:CC)

Wells Fargo & Company MN reduced its stake in Chemours Company (The) (NYSE:CC) by 38.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 204,645 shares of the specialty chemicals company’s stock after selling 126,847 shares during the quarter. Wells Fargo & Company MN owned about 0.11% of Chemours Company (The) worth $7,760,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. grew its position in Chemours Company (The) by 48,297.2% during the first quarter. BlackRock Inc. now owns 19,160,930 shares of the specialty chemicals company’s stock valued at $737,696,000 after acquiring an additional 19,121,339 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Chemours Company (The) by 1.2% in the first quarter. Vanguard Group Inc. now owns 18,773,273 shares of the specialty chemicals company’s stock worth $722,771,000 after purchasing an additional 215,900 shares during the last quarter. State Street Corp grew its holdings in shares of Chemours Company (The) by 35.1% in the first quarter. State Street Corp now owns 5,791,792 shares of the specialty chemicals company’s stock worth $222,987,000 after purchasing an additional 1,504,657 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Chemours Company (The) by 135.9% in the first quarter. Renaissance Technologies LLC now owns 3,031,400 shares of the specialty chemicals company’s stock worth $116,709,000 after purchasing an additional 1,746,100 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Chemours Company (The) by 10.5% in the second quarter. JPMorgan Chase & Co. now owns 1,966,582 shares of the specialty chemicals company’s stock worth $74,573,000 after purchasing an additional 186,228 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Wells Fargo & Company MN Has $7.76 Million Holdings in Chemours Company (The) (NYSE:CC)” was first posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/wells-fargo-company-mn-has-7-76-million-holdings-in-chemours-company-the-cc/1698789.html.

In related news, insider E Bryan Snell sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $46.24, for a total value of $462,400.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP David C. Shelton sold 19,000 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $53.68, for a total value of $1,019,920.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 77,142 shares of company stock worth $3,953,265. Insiders own 1.14% of the company’s stock.

Shares of Chemours Company (CC) opened at 57.55 on Tuesday. The company has a market capitalization of $10.64 billion, a P/E ratio of 37.66 and a beta of 3.60. The company has a 50-day moving average price of $51.25 and a 200 day moving average price of $44.05. Chemours Company has a 12-month low of $14.73 and a 12-month high of $57.68.

Chemours Company (The) (NYSE:CC) last issued its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.02. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.27 EPS. On average, equities analysts anticipate that Chemours Company will post $3.54 earnings per share for the current fiscal year.

Several analysts recently weighed in on the stock. Zacks Investment Research raised Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $61.00 price objective for the company in a research report on Tuesday, October 3rd. BidaskClub raised Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Argus reissued a “buy” rating and set a $55.00 price objective (up previously from $50.00) on shares of Chemours Company (The) in a research report on Thursday, August 10th. UBS AG raised Chemours Company (The) from a “sell” rating to a “neutral” rating and raised their price objective for the company from $36.00 to $50.00 in a research report on Monday, August 7th. Finally, J P Morgan Chase & Co lifted their price target on Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a research report on Friday, August 4th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Chemours Company (The) has an average rating of “Buy” and an average target price of $52.75.

Chemours Company (The) Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.